HC Wainwright Issues Positive Estimate for FENC Earnings

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for Fennec Pharmaceuticals in a report released on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.13) for the quarter, up from their prior estimate of ($0.20). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at ($0.28) EPS and FY2026 earnings at $0.63 EPS.

Several other brokerages have also recently issued reports on FENC. Wedbush reiterated an “outperform” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, March 10th. Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Stock Performance

NASDAQ:FENC opened at $6.51 on Thursday. The firm’s 50-day simple moving average is $6.40 and its 200 day simple moving average is $5.63. Fennec Pharmaceuticals has a 52 week low of $3.96 and a 52 week high of $11.49. The firm has a market cap of $179.43 million, a price-to-earnings ratio of -65.09 and a beta of 0.36.

Insider Buying and Selling at Fennec Pharmaceuticals

In related news, Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $6.08, for a total transaction of $60,800.00. Following the completion of the transaction, the director now directly owns 83,863 shares in the company, valued at $509,887.04. This represents a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders have sold 31,186 shares of company stock valued at $203,389. 10.98% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Advantage Alpha Capital Partners LP acquired a new position in Fennec Pharmaceuticals in the 3rd quarter worth about $264,000. State Street Corp raised its holdings in Fennec Pharmaceuticals by 2.2% in the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock valued at $1,641,000 after buying an additional 7,053 shares during the last quarter. Barclays PLC boosted its position in Fennec Pharmaceuticals by 274.3% during the 3rd quarter. Barclays PLC now owns 31,319 shares of the company’s stock worth $157,000 after buying an additional 22,951 shares during the period. Franklin Resources Inc. grew its holdings in Fennec Pharmaceuticals by 18.7% during the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock worth $74,000 after acquiring an additional 2,330 shares during the last quarter. Finally, Rhumbline Advisers increased its position in Fennec Pharmaceuticals by 12.9% in the 4th quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock valued at $217,000 after acquiring an additional 3,911 shares during the period. 55.51% of the stock is currently owned by institutional investors and hedge funds.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.